📊 IMDX Key Takeaways
Is Insight Molecular Diagnostics Inc. (IMDX) a Good Investment?
Insight Molecular Diagnostics is technically insolvent with negative stockholders equity of -$10.7M and is burning $7.6M annually in operating losses against only $32K in revenue. While the company maintains $28.2M in cash, the current cash burn rate provides limited runway and will require substantial capital raises or dramatic revenue acceleration to achieve viability.
Despite a step-change in revenue and a solid gross margin profile, Insight Molecular Diagnostics remains deeply unprofitable with severe operating losses and negative free cash flow. Negative stockholders' equity, weak liquidity, and ongoing cash burn suggest a high probability of further capital raises and dilution until scale and cost discipline materially improve.
Insight Molecular Diagnostics Inc. Key Strengths (IMDX)
- Cash position of $28.2M provides near-term liquidity buffer
- Gross margin of 46.9% demonstrates product margin potential if revenue scales
- Strong percentage revenue growth YoY (+3820%) indicates early-stage commercial traction
- Explosive YoY revenue growth from new traction
- Gross margin of 56.7% supports unit economics
- Low absolute long-term debt ($3.2M)
IMDX Stock Risks: Insight Molecular Diagnostics Inc. Investment Risks
- Negative stockholders equity of -$10.7M indicates balance sheet insolvency
- Operating cash burn of $7.6M annually creates urgent capital requirements within 3-4 years
- Minimal revenue of $32K in latest period suggests pre-commercial stage with extreme execution risk
- Operating margin of -13790.6% reflects severe operational inefficiency and unsustainable cost structure
- Accumulated losses and negative equity indicate prior capital destruction
- Dilution risk from required future capital raises to fund operations
- Negative stockholders’ equity with liabilities exceeding assets
- Severe operating losses and -625.6% FCF margin
- Limited cash runway implying dilution/going-concern risk
Key Metrics to Watch
- Cash balance and quarterly burn rate trajectory
- Revenue acceleration path to meaningful scale (minimum $1M+ quarterly)
- Operating expense reduction or achievement of operating profitability milestone
- Debt covenant compliance and refinancing needs
- Capital raise announcements and dilution impact
- Operating cash burn and cash runway (cash vs OCF)
- Revenue growth sustainability with gross margin ≥55%
Insight Molecular Diagnostics Inc. (IMDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.54x current ratio provides a solid financial cushion.
IMDX Profit Margin, ROE & Profitability Analysis
IMDX vs Healthcare Sector: How Insight Molecular Diagnostics Inc. Compares
How Insight Molecular Diagnostics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Insight Molecular Diagnostics Inc. Stock Overvalued? IMDX Valuation Analysis 2026
Based on fundamental analysis, Insight Molecular Diagnostics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Insight Molecular Diagnostics Inc. Balance Sheet: IMDX Debt, Cash & Liquidity
IMDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Insight Molecular Diagnostics Inc.'s revenue has declined by 48% over the 5-year period, indicating business contraction. The most recent EPS of $-4.66 indicates the company is currently unprofitable.
IMDX Revenue Growth, EPS Growth & YoY Performance
IMDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $32.0K | -$4.3M | $-0.12 |
| Q3 2025 | $115.0K | -$10.9M | $-0.34 |
| Q2 2025 | $104.0K | -$4.5M | $-0.30 |
| Q1 2025 | $176.0K | -$6.7M | $-0.26 |
| Q3 2024 | $115.0K | -$6.5M | $-0.81 |
| Q2 2024 | $104.0K | -$4.5M | $-0.36 |
| Q1 2024 | $176.0K | $3.0M | $0.40 |
| Q3 2023 | $67.0K | -$6.5M | $-0.81 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Insight Molecular Diagnostics Inc. Dividends, Buybacks & Capital Allocation
IMDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Insight Molecular Diagnostics Inc. (CIK: 0001642380)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMDX
What is the AI rating for IMDX?
Insight Molecular Diagnostics Inc. (IMDX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMDX's key strengths?
Claude: Cash position of $28.2M provides near-term liquidity buffer. Gross margin of 46.9% demonstrates product margin potential if revenue scales. ChatGPT: Explosive YoY revenue growth from new traction. Gross margin of 56.7% supports unit economics.
What are the risks of investing in IMDX?
Claude: Negative stockholders equity of -$10.7M indicates balance sheet insolvency. Operating cash burn of $7.6M annually creates urgent capital requirements within 3-4 years. ChatGPT: Negative stockholders’ equity with liabilities exceeding assets. Severe operating losses and -625.6% FCF margin.
What is IMDX's revenue and growth?
Insight Molecular Diagnostics Inc. reported revenue of $32.0K.
Does IMDX pay dividends?
Insight Molecular Diagnostics Inc. does not currently pay dividends.
Where can I find IMDX SEC filings?
Official SEC filings for Insight Molecular Diagnostics Inc. (CIK: 0001642380) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMDX's EPS?
Insight Molecular Diagnostics Inc. has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IMDX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Insight Molecular Diagnostics Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IMDX stock overvalued or undervalued?
Valuation metrics for IMDX: ROE of N/A (sector avg: 15%), net margin of -13,406.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IMDX's AI grade for 2026?
Our dual AI analysis gives Insight Molecular Diagnostics Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMDX's free cash flow?
Insight Molecular Diagnostics Inc.'s operating cash flow is $-7.6M, with capital expenditures of $613.0K. FCF margin is -25,787.5%.
How does IMDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -13,406.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.54 (avg: 2).